Phase 3 Trial Shows Positive Results for Oral Acne Drug Denifanstat
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The regenerative biostimulator is now certified for use in four new body areas.